Home > Insider Trading > Filing (0001209191-21-030397)

Filing Details

Accession Number:: 0001209191-21-030397
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-05-05 13:00:00
Reporting Period:: 2021-05-03

Accepted Time:: 2021-05-05 17:13:09
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1770787	10X Genomics Inc.	TXG	Laboratory Analytical Instruments (3826)	455614458

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1786386	J. Justin Mcanear	C/O 10X Genomics, Inc. 6230 Stoneridge Mall Road Pleasanton CA 94588	Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Class A Common Stock	Acquisiton	2021-05-03	10,000	$5.04	40,357	No	4	M	Direct
Class A Common Stock	Disposition	2021-05-03	600	$189.57	39,757	No	4	S	Direct
Class A Common Stock	Disposition	2021-05-03	1,900	$190.63	37,857	No	4	S	Direct
Class A Common Stock	Disposition	2021-05-03	2,700	$191.77	35,157	No	4	S	Direct
Class A Common Stock	Disposition	2021-05-03	3,706	$192.46	31,451	No	4	S	Direct
Class A Common Stock	Disposition	2021-05-03	794	$193.40	30,657	No	4	S	Direct
Class A Common Stock	Disposition	2021-05-03	200	$194.92	30,457	No	4	S	Direct
Class A Common Stock	Disposition	2021-05-03	100	$198.09	30,357	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Class A Common Stock	Stock Option (right to buy)	Disposition	2021-05-03	10,000	$0.00	10,000	$5.04

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
430,159		2028-11-02	No	4	M	Direct

Footnotes

This option exercise and the sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.
This transaction was executed in multiple trades at prices ranging from $189.12 to $189.93. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
This transaction was executed in multiple trades at prices ranging from $190.10 to $191.02. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
This transaction was executed in multiple trades at prices ranging from $191.08 to $192.02. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
This transaction was executed in multiple trades at prices ranging from $192.06 to $192.995. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
This transaction was executed in multiple trades at prices ranging from $193.07 to $193.99. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
This option, originally for 600,000 shares, of which 169,841 shares have been exercised, vested as to one-fourth of the shares on October 8, 2019 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.